Navigation Links
Hypogonadism in Medical Technology

FDA Accepts Complete Response Submission to New Drug Application for NEBIDO(R)

... in Europe and other territories. About hypogonadism Male hypogonadism is an increasingly recognized medical condition ... impair quality of life. Common effects of hypogonadism include decreased sexual desire, erectile ...

Indevus Announces Submission of New Drug Application

... reported were comparable to other injectable hypogonadism treatments reported in the literature. There were ... Schering Pharma AG, Germany in July 2005. About hypogonadism Male hypogonadism is an increasingly recognized medical ...

Novel Testosterone Gel Significantly Improves Insulin Sensitivity and Sexual Function in Hypogonadal Men With Type 2 Diabetes and Metabolic Syndrome

... 40-69 years, it is estimated that there are about 481,000 new cases of hypogonadism per year. Overall, approximately 2.4 million U.S. men suffer from the condition.(1) hypogonadism results from a deficiency in testosterone secretion that may occur ...

Indevus Presents Successful Phase III NEBIDO(R) Data at American Urological Association

... previously announced, are based on a Phase III study in which men with hypogonadism and low serum testosterone levels prior to entering the study were treated ... Schering Pharma AG, Germany in July 2005. About Hypogonadism Male hypogonadism is an increasingly recognized medical condition characterized by a reduced ...

QuatRx Completes Enrollment of Ophena(TM)(Ospemifene Tablets) Final Pivotal Phase 3 Study in Women with Postmenopausal Vaginal Atrophy

... program. Fispemifene is a new selective estrogen receptor antagonist that is in Phase 2 as an oral treatment for the symptoms of secondary hypogonadism and other conditions in men. Sobetirome, a novel, selective thyroid receptor beta agonist, is in Phase 1 as a potential treatment for dyslipidemia. ...

QuatRx Pharmaceuticals Announces Additional Data From Phase 3 Study for Ophena(TM) (Ospemifene Tablets) Showing Improvements in Clinical Symptoms of Vulvovaginal Atrophy

... program. Fispemifene is a new selective estrogen receptor antagonist that is in Phase 2 studies as an oral treatment for the symptoms of secondary hypogonadism in men. Sobetirome, a novel, selective thyroid receptor beta agonist, is in Phase 1 studies as a potential treatment for dyslipidemia. Asord(TM) ...

QuatRx Initiates Second Phase 3 Study of Ophena(TM) (Ospemifene Tablets) in Women With Postmenopausal Vaginal Syndrome

... program. Fispemifene is a new selective estrogen receptor antagonist that is in Phase 2 studies as an oral treatment for the symptoms of secondary hypogonadism in men. Sobetirome, a novel, selective thyroid receptor beta agonist, is in Phase 1 as a potential treatment for dyslipidemia. Becocalcidiol, a novel ...

Quatrx Pharmaceuticals Presents Results From Ophena(TM) (Ospemifene Tablets) Phase 3 Study Related to Treatment of Symptoms of Vulvovaginal Atrophy

... program. Fispemifene is a new selective estrogen receptor antagonist that is in Phase 2 studies as an oral treatment for the symptoms of secondary hypogonadism in men. Sobetirome, a novel, selective thyroid receptor beta agonist, is in Phase 1 studies as a potential treatment for dyslipidemia. Asord(TM) ...

Auxilium Pharmaceuticals, Inc. Announces XIAFLEX(TM) Meets Primary Endpoint With Statistical Significance (p<0.001) in CORD I Pivotal Phase III Study for Dupuytren's Contracture

... endocrinologists, orthopedists and select primary care physicians. Auxilium markets Testim(R) 1%, a topical testosterone gel, for the treatment of hypogonadism through its approximately 190-person sales and marketing team. Auxilium has four projects in clinical development. XIAFLEX(TM) (clostridial ...

QuatRx Pharmaceuticals Announces Presentation of Further Data from Ophena(TM) (Ospemifene) Phase 3 Study for Treatment of Symptoms of Vulvovaginal Atrophy

... program. Fispemifene is a new selective estrogen receptor antagonist that is in Phase 2 studies as an oral treatment for the symptoms of secondary hypogonadism in men. Sobetirome, a novel, selective thyroid receptor beta agonist, is in Phase 1 studies as a potential treatment for dyslipidemia. Asord(TM) ...

Indevus Reports Additional Positive Phase III Trial Data for NEBIDO(R)

... replacement therapies. Indevus acquired U.S. rights to NEBIDO from Bayer Schering Pharma AG, Germany in July 2005. About Hypogonadism Male hypogonadism is an increasingly recognized medical condition characterized by a reduced or absent secretion of testosterone from the testes. Reduced testosterone ...

QuatRx Pharmaceuticals Announces Positive Phase 3 Results for Study of Ophena(TM) (ospemifene) to Treat Postmenopausal Vaginal Syndrome

... programs. Fispemifene is a new selective estrogen receptor antagonist that is in Phase 2 studies as an oral treatment for the symptoms of secondary hypogonadism in men. QRX-431, a novel, selective thyroid receptor beta agonist, is in Phase 1 studies as a potential treatment for lipid disorders and obesity. ...

QuatRx Completes Patient Enrollment in Phase 3 Study of Ophena(TM) in Women with Postmenopausal Vaginal Syndrome

... programs. Fispemifene is a new, selective estrogen receptor antagonist that is in Phase 2 studies as an oral treatment for the symptoms of secondary hypogonadism in men. QRX-431, a novel, selective thyroid receptor beta agonist, is in Phase 1 studies as a potential treatment for lipid disorders and obesity. ...

Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)

... endocrinologists, orthopedists and select primary care physicians. Auxilium markets Testim(R) 1%, a topical testosterone gel, for the treatment of hypogonadism through its approximately 190-person sales and marketing team. Auxilium has four projects in clinical development. XIAFLEX(TM) (clostridial ...

Repros' Androxal Shows Highly Statistically Significant Positive Effects in Men with Secondary Hypogonadism

... or hypothalamic dysfunction, when diagnosing hypogonadism in men." Although the syndrome of secondary hypogonadism is characterized by the objective measurements of ... potential to change the way in which secondary hypogonadism is treated in the future." Repros anticipates ...

Indevus Reports Positive Data From Phase III NEBIDO Trial

... under development for the treatment of male hypogonadism which the Company licensed from Bayer Schering ... Schering Pharma AG, Germany in July 2005. About hypogonadism Male hypogonadism is an increasingly recognized medical condition ...

New Poll Shows Men, Women Incorrectly Blame Symptoms of Low Testosterone on Normal Aging

... of their current relationship. About hypogonadism (Low Testosterone) Physical signs of hypogonadism can include incomplete sexual development, body ... sperm production. Symptoms associated with hypogonadism can include reduced sexual desire, depression, ...

Auxilium Announces New Data That Show Total Testosterone Blood Levels Increase Significantly Following Switch from AndroGel(R) to Testim(R)

... an initial inadequate response. About hypogonadism Low testosterone ("Low T"), or hypogonadism, is ... testosterone production. Physical signs of hypogonadism can include incomplete sexual development, body ... a topical testosterone gel, for the treatment of hypogonadism through its approximately 190-person sales and ...

Columbia Laboratories Reports Preliminary Findings from the Ongoing Data Analysis of the Phase III Clinical Study of PROCHIEVE 8% (progesterone gel) to Prevent Preterm Birth

... (progesterone gel) for the treatment of secondary amenorrhea. The Company also markets STRIANT(R) (testosterone buccal system) for the treatment of hypogonadism in men. For more information, please visit www.columbialabs.com. Safe Harbor Statement Under the Private Securities Litigation Reform Act of 1995: ...

Auxilium Pharmaceuticals to Present at the 2007 CEUT Emerging Growth Opportunities Conference

... orthopedists and select primary care physicians. Auxilium markets Testim(R) 1%, a topical testosterone gel, for the treatment of hypogonadism through its approximately 190-person sales and marketing team. Auxilium has four projects in clinical development. AA4500, an injectable collagenase ...
Other Contents
(Date:7/11/2014)... 2014 Research and Markets has ... Market - Industry Analysis Size Share Growth Trends and ... http://photos.prnewswire.com/prnh/20130307/600769 The ... a need for high level security in both private ... such as username and passwords, tokens etc. are vulnerable ...
(Date:7/10/2014)... 2014  The American Academy of Forensic Sciences ... and Technology (NIST) and the Department of Justice ... forensic science expert members to the Forensic Science ... of the NIST,s Organization of Scientific Area Committees ... appointments made to the new FSSB that has ...
(Date:7/10/2014)... BLUE BELL, Pa. , July 2, 2014  Unisys ... The Netherlands , Unisys Nederland N.V., today announced that ... (DJI) to deliver, implement and manage a new Basic Provision ... . Unisys won the contract with a ... for identity management software. The term of the contract is ...
Breaking Biology News(10 mins):International Biometrics Technology Market - Industry Analysis Size Share Growth Trends and Forecast to 2019 2Ten Members of the American Academy of Forensic Sciences Appointed to Forensic Science Standards Board (FSSB) 2Ten Members of the American Academy of Forensic Sciences Appointed to Forensic Science Standards Board (FSSB) 3Unisys Delivers New Basic Provision Biometrics Solution to Dutch Custodial Institutions Service 2Unisys Delivers New Basic Provision Biometrics Solution to Dutch Custodial Institutions Service 3
(Date:7/11/2014)... Children who have emergency surgery on weekends are ... death than those who have weekday surgeries, according ... Hopkins researchers noted that the risk of death ... nearly 440,000 simple emergency surgeries that children across ... The surgeries are considered generally safe and ...
(Date:7/11/2014)... According to a new market research ... Communication Technology (ZigBee, Z-Wave, Bluetooth, Wi-Fi, NFC, RFID), Application ... Transportation, Agriculture) & Geography - Global Trends & Forecasts ... Things market was worth $1029.5 Billion in 2013, and ... an estimated CAGR of 4.08% from 2014 to 2020. ...
(Date:7/11/2014)... Miriam Hospital have found that people with mobility ... of smoking than those without mobility impairments. Additionally, ... attempt quitting than those without mobility impairments, and ... this population. The study and its findings are ... American Journal of Public Health . ...
(Date:7/11/2014)... HealthDay Reporter THURSDAY, July ... children from the worldwide scourge of dengue fever was somewhat ... vaccine only prevented dengue fever in 56 percent of the ... it protected more than 88 percent of them from severe ... hospitalization, and sometimes death. "This vaccine has already proven ...
(Date:7/11/2014)... 2014 Last month Watkins Insurance Group ... joins the agency as a specialist in insurance and ... a Bachelor’s Degree in Business Administration from Texas State ... will manage everything from performance and payment bonds, license ... specialized needs for those in the asphalt supplier industry. ...
Breaking Medicine News(10 mins):Health News:Emergency Surgeries on Weekends Riskier for Kids: Study 2Health News:Internet of Things Technology & Application Market Worth $1423.09 Billion by 2020 – New Report by MarketsandMarkets 2Health News:Internet of Things Technology & Application Market Worth $1423.09 Billion by 2020 – New Report by MarketsandMarkets 3Health News:Internet of Things Technology & Application Market Worth $1423.09 Billion by 2020 – New Report by MarketsandMarkets 4Health News:Miriam Hospital study examines smoking prevalence 2Health News:Dengue Fever Vaccine Shows Some Promise in Trial 2Health News:Dengue Fever Vaccine Shows Some Promise in Trial 3
Other TagsOther Tags